8103 related articles for article (PubMed ID: 16078447)
21. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
[TBL] [Abstract][Full Text] [Related]
22. Clinical and immunologic effects of T-activin therapy in early stage melanoma patients.
Stanojević-Bakić N; Milosević D; Vucković-Dekić L; Sasić M; Marković L
Neoplasma; 1996; 43(4):245-52. PubMed ID: 8931749
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells.
Konjević G; Mirjacić Martinović K; Jurisić V; Babović N; Spuzić I
Biomarkers; 2009 Jun; 14(4):258-70. PubMed ID: 19489688
[TBL] [Abstract][Full Text] [Related]
24. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
Karavodin LM; Golub SH
Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
[TBL] [Abstract][Full Text] [Related]
25. Subpopulations of the peripheral lymphocytes in the early clinical forms of Lyme disease.
Zajkowska JM; Hermanowska-Szpakowicz T
Med Sci Monit; 2000; 6(2):278-84. PubMed ID: 11208323
[TBL] [Abstract][Full Text] [Related]
26. Changes in T and B lymphocyte subpopulations before, during and after chemotherapy for malignant melanoma.
Bernengo MG; Lisa F; Meregalli M; Doveil GC
Int J Tissue React; 1984; 6(6):505-11. PubMed ID: 6335712
[TBL] [Abstract][Full Text] [Related]
27. Two cases of metastatic malignant melanoma of the lower limb treated with hyperthermic isolated limb perfusion and concomitant infusion of either carboplatin or beta-interferon.
Nakayama J; Takeuchi M; Mayumi H; Nagae S; Matsuda K; Yasui H; Takahashi S; Hori Y
J Dermatol; 1996 Jan; 23(1):6-15. PubMed ID: 8720252
[TBL] [Abstract][Full Text] [Related]
28. Abnormalities of peripheral blood T lymphocytes and natural killer cells in alcoholic hepatitis persist after a 3-month withdrawal period.
Laso FJ; Madruga JI; López A; Ciudad J; Alvarez-Mon M; San Miguel J; Orfao A
Alcohol Clin Exp Res; 1997 Jun; 21(4):672-6. PubMed ID: 9194923
[TBL] [Abstract][Full Text] [Related]
29. The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
Hernberg MM; Hahka-Kemppinen MH; Pyrhönen SO
Melanoma Res; 2004 Dec; 14(6):493-500. PubMed ID: 15577320
[TBL] [Abstract][Full Text] [Related]
30. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
Najar HM; Dutz JP
J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
[TBL] [Abstract][Full Text] [Related]
31. [Are immunological treatments beneficial for malignant melanoma of the skin?].
Vihinen P; Vuoristo MS; Hernberg M; Pyrhönen S
Duodecim; 2010; 126(14):1701-10. PubMed ID: 20804089
[TBL] [Abstract][Full Text] [Related]
32. Regulatory T cells and other lymphocyte subpopulations in patients with melanoma developing interferon-induced thyroiditis during high-dose interferon-α2b treatment.
Soldevila B; Alonso N; Martínez-Arconada MJ; Granada ML; Boada A; Vallejos V; Fraile M; Fernández-Sanmartín MA; Pujol-Borrell R; Puig-Domingo M; Sanmartí A; Martínez-Cáceres EM
Clin Endocrinol (Oxf); 2013 Apr; 78(4):621-8. PubMed ID: 22957689
[TBL] [Abstract][Full Text] [Related]
33. Unique functional status of natural killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy.
Fregni G; Perier A; Pittari G; Jacobelli S; Sastre X; Gervois N; Allard M; Bercovici N; Avril MF; Caignard A
Clin Cancer Res; 2011 May; 17(9):2628-37. PubMed ID: 21224372
[TBL] [Abstract][Full Text] [Related]
34. Decreased expression of pSTAT, IRF-1 and DAP10 signalling molecules in peripheral blood lymphocytes of patients with metastatic melanoma.
Mirjačić Martinović K; Srdić-Rajić T; Babović N; Džodić R; Jurišić V; Konjević G
J Clin Pathol; 2016 Apr; 69(4):300-6. PubMed ID: 26442832
[TBL] [Abstract][Full Text] [Related]
35. Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.
Redman BG; Flaherty L; Chou TH; Nakeff A; Pillote K; Kaplan J
J Immunother (1991); 1991 Apr; 10(2):147-51. PubMed ID: 2043595
[TBL] [Abstract][Full Text] [Related]
36. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
Kirkwood JM; Richards T; Zarour HM; Sosman J; Ernstoff M; Whiteside TL; Ibrahim J; Blum R; Wieand S; Mascari R
Cancer; 2002 Sep; 95(5):1101-12. PubMed ID: 12209697
[TBL] [Abstract][Full Text] [Related]
37. Impaired perforin-dependent NK cell cytotoxicity and proliferative activity of peripheral blood T cells is associated with metastatic melanoma.
Jović V; Konjević G; Radulović S; Jelić S; Spuzić I
Tumori; 2001; 87(5):324-9. PubMed ID: 11765182
[TBL] [Abstract][Full Text] [Related]
38. Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma.
Heise R; Amann PM; Ensslen S; Marquardt Y; Czaja K; Joussen S; Beer D; Abele R; Plewnia G; Tampé R; Merk HF; Hermanns HM; Baron JM
PLoS One; 2016; 11(1):e0146325. PubMed ID: 26735690
[TBL] [Abstract][Full Text] [Related]
39. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
[TBL] [Abstract][Full Text] [Related]
40. The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy.
Hernberg M; Muhonen T; Turunen JP; Hahka-Kemppinen M; Pyrhönen S
J Clin Oncol; 1996 May; 14(5):1690-6. PubMed ID: 8622089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
